Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and cyclofem) on lipid and lipoprotein metabolism
United-Nations-Development-Programme, U.-Nations-Population-Fund; Organization, W.-Health; Bank, W.; Development, S.-Programme-Of-Research; Regulation, R.-Training-In-Human-Reproduction-And-Task-Force-On-Long-Acting-Systemic-Agents-For-Fertility
Contraception 56(4): 193-206
1997
ISSN/ISBN: 0010-7824 DOI: 10.1016/s0010-7824(97)00139-xDocument Number: 259374
A 1-year longitudinal multicenter study was undertaken to monitor the effects on lipid metabolism of two once-a-month injectable contraceptive preparations, Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate and Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate). A total of 357 volunteers from four centers (Hangzhou, Havana, Jakarta, and Shanghai) were monitored during one pretreatment cycle, the third and ninth injection intervals, and during one posttreatment cycle, approximately 3 months after the 9-month period of treatment was completed. With both preparations, changes were observed at 3 months of use, remained essentially unchanged during treatment, and returned to pretreatment levels after discontinuation of use. With Mesigyna, changes consisted mostly of decreases in high density lipoprotein cholesterol (HDL-C, -10%), apolipoprotein AI (-9%), and triglycerides (-15%). With Cyclofem, changes were even smaller. With both, variations in lipid levels mirrored closely the pharmacokinetics of each preparation and the biphasic nature of the injection intervals.